0T6G Stock Chart & Stats
$15.28
$0.22(1.44%)
At close: 4:00 PM EDT
$15.28
$0.22(1.44%)
Day’s Range― - ―
52-Week Range$1.62 - $23.50
Previous CloseN/A
Volume2.53K
Average Volume (3M)12.87K
Market Cap
$481.67M
Enterprise Value$158.19
Total Cash (Recent Filing)$106.27M
Total Debt (Recent Filing)$5.30M
Price to Earnings (P/E)5.8
Beta0.05
Next Earnings
Nov 05, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.79
Shares Outstanding29,769,466
10 Day Avg. Volume36,331
30 Day Avg. Volume12,873
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.97
Price to Sales (P/S)0.76
P/FCF Ratio-1.22
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$41.00Price Target Upside168.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.46
Revenue Forecast (FY)$400.00K
Bulls Say, Bears Say
Bulls Say
Clinical Proof-of-conceptRobust Phase 2a topline results give durable clinical proof-of-concept for bempikibart’s IL-7Rα approach, showing efficacy and a favorable safety profile. This materially lowers development risk, enables a registration-directed path and broader indication expansion potential over the next 2–3 years.
Institutional Funding SupportA $55M placement led by top healthcare investors materially strengthens the company’s liquidity to advance clinical programs, reduces near-term financing risk, and signals external validation. Institutional backers improve access to future rounds, partnerships and CRO engagement credibility.
Improved Balance Sheet LeverageCurrent low debt relative to equity and the recent payoff of a ~$6.8M SVB loan simplify capital structure and reduce solvency risk. Manageable leverage gives the company financial flexibility to fund trials, negotiate partnerships, and withstand development timelines without immediate distress.
Bears Say
Negative Cash GenerationSustained negative operating and free cash flow means R&D and trial execution are not self-funded. Persistent cash burn forces recurring capital raises, increases dilution risk, and makes program timelines sensitive to capital market conditions and investor appetite over the medium term.
Volatile Earnings HistorySharp multi-year swings from deep losses to a recent TTM profit indicate unstable revenue and earnings quality. This volatility reduces confidence in repeatable margins, complicates forecasting, partner negotiations and long-term planning for a development-stage biotech dependent on milestone timing.
Ongoing Reliance On Equity FinancingRecurring equity raises and recent share-sale filings underscore dependence on capital markets. Continued dilution risks eroding shareholder value, creates supply overhang that can impact strategic negotiations, and reflects limited near-term options to fund programs without external financing.
Q32 Bio News
0T6G FAQ
What was Q32 Bio’s price range in the past 12 months?
Q32 Bio lowest share price was $1.62 and its highest was $23.50 in the past 12 months.
What is Q32 Bio’s market cap?
Q32 Bio’s market cap is $481.67M.
When is Q32 Bio’s upcoming earnings report date?
Q32 Bio’s upcoming earnings report date is Nov 05, 2026 which is in 69 days.
How were Q32 Bio’s earnings last quarter?
Q32 Bio released its earnings results on Aug 05, 2026. The company reported -$0.44 earnings per share for the quarter, beating the consensus estimate of -$0.46 by $0.02.
Is Q32 Bio overvalued?
According to Wall Street analysts Q32 Bio’s price is currently Undervalued.
Does Q32 Bio pay dividends?
Q32 Bio pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Q32 Bio dividends here
What is Q32 Bio’s EPS estimate?
Q32 Bio’s EPS estimate is -0.32.
How many shares outstanding does Q32 Bio have?
Q32 Bio has 29,769,466 shares outstanding.
What happened to Q32 Bio’s price movement after its last earnings report?
Q32 Bio reported an EPS of -$0.44 in its last earnings report, beating expectations of -$0.46. Following the earnings report the stock price went up 6.945%.
Which hedge fund is a major shareholder of Q32 Bio?
Currently, no hedge funds are holding shares in GB:0T6G
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Q32 Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.00 (168.32% Upside)
$41.00 (168.32% Upside)
Blogger Sentiment
Bullish
GB:0T6G Sentiment 86%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $29.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
555.84%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
75.25%
Trailing 12-Months
Company Description
Q32 Bio
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
0T6G Stock 12 Month Forecast
Average Price Target
$41.00
▲(168.32% Upside)
Technical Analysis
Tempest Therapeutics
―
PDS Biotechnology
―
Grace Therapeutics
―
CalciMedica
―
Senti Biosciences
―